The PD‐1 inhibitor pembrolizumab has obtained regulatory approval for first‐line monotherapy in advanced NSCLC patients demonstrating ≥ 1% PD‐L1 tumor proportion score (TPS) [22]. This evidence concerns the gene PDCD1 and neoplasm.